Efficacy and safety of capecitabine-based first-line chemotherapy in advanced or metastatic breast cancer: a meta-analysis of randomised controlled trials
Tóm tắt
Từ khóa
Tài liệu tham khảo
Pegram, 2007, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, Arch Pathol Lab Med, 131, 18, 10.5858/2007-131-18-ASOCCO
Jemal, 2012, Global cancer statistics, CA Cancer J Clin, 65, 87
Mamounas, Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial, Lancet Oncol, 15, 156
El Saghir, ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)dagger, Ann Oncol, 25, 1871
Luck, 2003, Multicenter phase II study of oral capecitabine (Xeloda(“)) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy, Ann Oncol, 14, 1227, 10.1093/annonc/mdg346
Mavroudis, A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer, Ann Oncol, 23, 1164
Harrison, 2009, Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer, J Clin Oncol, 27, 1753, 10.1200/JCO.2007.15.8485
Laws, 2001, Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer, Ann Oncol, 12, 1247, 10.1023/A:1012281104865
Seynaeve, A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG, Ann Oncol, 25, 599
McQuay, 1996, Assessing the quality of reports of randomized clinical trials: is blinding necessary?, Control Clin Trials, 17, 1, 10.1016/0197-2456(95)00134-4
Stewart, 1998, Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints, Stat Med, 17, 2815, 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
Eidtmann, Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group, Breast Cancer Res Treat, 139, 779
Boven, Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial, Eur J Cancer, 50, 3077
Colucci, A multicenter phase II randomized trial of docetaxel/gemcitabine versus docetaxel/capecitabine as first-line treatment for advanced breast cancer: a Gruppo Oncologico Italia Meridionale study, Oncology, 81, 230
Coates, Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer, J Clin Oncol, 29, 4498
Perol, Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer, Oncology, 80, 262
Torres, Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer, J Clin Oncol, 28, 976
Georgoulias, Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer, Ann Oncol, 21, 48
Cardoso, Management of locally advanced breast cancer-perspectives and future directions, Nat Rev Clin Oncol, 12, 312
Higashi, 2000, Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients, Oncol Rep, 7, 945
O'Shaughnessy, Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer, Clin Breast Cancer, 11, 349
Martin, Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?, Ann Oncol, 21, 2145
Traina, Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer, Breast Cancer Res Treat, 131, 111
Traina, Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer, Cancer, 117, 4125
Shin, Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer, Breast Cancer, 17, 233
Harbeck, Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer, Oncologist, 17, 476
McGuire, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106